Overcoming Delivery Obstacles with Cholesterol Nanodomains

T. Anchordoquy
University of Colorado Denver, US

Keywords: nanodomains, drug delivery


The use of “nano-sized” delivery vehicles dates back to the advent of liposomes in the 1960s. Although there is a long history of liposomes being investigated for drug delivery, only a handful of pharmaceutical products have been commercialized. Many studies since the 1970s have contributed to our current understanding regarding the problems/barriers associated with employing nanoparticles, especially lipid-based systems, for drug delivery. Furthermore, the goal of delivering nucleic acids to the interior of the target cell presents additional complications to the formidable barriers associated with delivering traditional small-molecule therapeutics. While modern analytical techniques allow present-day scientists to investigate barriers with unprecedented precision, these technical advancements have yielded very little insight into strategies for circumventing delivery barriers that were identified decades ago. The talk will focus on major barriers surrounding stability, protein adsorption, targeting, intracellular trafficking and toxicity. The limitations of current delivery strategies will be critically evaluated, and the advantages of employing vehicles possessing cholesterol domains will be presented.